Lineage Cell Therapeutics Inc (LCTX) Stock Price, Quote & News

Company Profile

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the tre...

Industry: Biotechnology

Sector: Healthcare

Phone: 442 287 8990

Website: www.lineagecell.com

Address:

2173 Salk Avenue, Suite 200, Carlsbad, United States

JohnPDaly Aug. 9 at 1:03 PM

$LCTX $MDWD https://x.com/learnbiotech/status/1954120602836496584?s=12

0 · Reply

Trak2 Aug. 9 at 3:53 AM

$LCTX any bold predictions for Tuesday? Winner gets a rocket for his desk. Lol. I’m predicting we’re finally going to hear more about hearing loss.😝trial?

2 · Reply

ChasRiggs Aug. 9 at 1:38 AM

$LCTX kept it right under $1 for options expectation. Intrigued.

1 · Reply

Gromit00 Aug. 8 at 6:01 PM

$LCTX looks like Neal got richer today with Monster, Inc stock up a healthy 6%.

1 · Reply

Wawawiiwa Aug. 8 at 5:05 PM

$LCTX

0 · Reply

broke_millionaire Aug. 8 at 3:53 PM

$LCTX $AVXL $XBI SRPT institutional ownership just skyrocketed to 116%

3 · Reply

Logic102 Aug. 8 at 3:52 PM

$LCTX $AVXL $XBI When looking at a biotech investment, here are my filters before a major accumulation: does the company have solid institutional ownership? Is the Pipeline diverse and solid? Has the product/technology proven to be very safe? Is the Total Addressable Market large and growing? Does the scientific MOA and the trial data point to clear advantages over the competition? Does the manufacturing process have advantages over the competition? Does the company have financial stability? Major Bonus points for an upstream Method of Action that meets currently unmet medical needs. Bonus points for treating conditions related to aging.

2 · Reply

imatisse Aug. 8 at 1:57 PM

$LCTX Tariffs are paid by the US companies that import goods, I don’t know from : the cell manufacturing CellCure Neurosciences … so No money is flowing into the USA. It's just going from American companies … Lineage? (and, eventually, American consumers) to the government.

0 · Reply

JohnPDaly Aug. 8 at 1:25 PM

$LCTX the race to a trillion bucks has a lot of entrants. https://x.com/geneinvesting/status/1953570907122814991?s=12

2 · Reply

DiligentInvesting Aug. 8 at 12:19 PM

$LCTX I think there´s a rather considerate pump potential with the upcoming ER. Let´s see. STBM.

1 · Reply

Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Aug 4, 2025, 8:00 AM EDT - 5 days ago

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

Jun 23, 2025, 7:39 AM EDT - 6 weeks ago

Two Biotech Stocks Poised For Big Moves On Monday

SANA

Jun 23, 2025, 7:00 AM EDT - 6 weeks ago

OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

Jun 5, 2025, 8:00 AM EDT - 2 months ago

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

May 14, 2025, 8:00 AM EDT - 3 months ago

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 13, 2025, 5:53 PM EDT - 3 months ago

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:01 PM EDT - 3 months ago

Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 8:00 AM EDT - 3 months ago

RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025

May 1, 2025, 8:00 AM EDT - 3 months ago

Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

Apr 22, 2025, 8:00 AM EDT - 3 months ago

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

Apr 21, 2025, 8:00 AM EDT - 3 months ago

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

Mar 10, 2025, 8:16 PM EDT - 5 months ago

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call Transcript

Mar 10, 2025, 4:05 PM EDT - 5 months ago

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 5, 2025, 8:00 AM EST - 5 months ago

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

Feb 11, 2025, 8:00 AM EST - 6 months ago

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

Feb 4, 2025, 8:00 AM EST - 6 months ago

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

Jan 27, 2025, 4:05 PM EST - 6 months ago

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

Jan 6, 2025, 8:00 AM EST - 7 months ago

Lineage Cell Therapeutics Issues Letter to Stockholders

Nov 21, 2024, 5:00 PM EST - 9 months ago

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

Nov 20, 2024, 8:00 AM EST - 9 months ago

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

Nov 14, 2024, 9:39 PM EST - 9 months ago

Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 4:01 PM EST - 9 months ago

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 8:00 AM EST - 9 months ago

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

Oct 14, 2024, 8:00 AM EDT - 10 months ago

Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

Sep 25, 2024, 8:00 AM EDT - 11 months ago

OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

Sep 18, 2024, 8:00 AM EDT - 11 months ago

Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 10, 2024, 12:03 AM EDT - 1 year ago

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index

May 30, 2024, 8:00 AM EDT - 1 year ago

Lineage to Present at 2024 BIO International Convention

May 21, 2024, 8:00 AM EDT - 1 year ago

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

May 10, 2024, 12:33 AM EDT - 1 year ago

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 8:00 AM EDT - 1 year ago

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

May 2, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

Apr 29, 2024, 4:30 PM EDT - 1 year ago

Lineage Announces Changes to Board of Directors

Apr 23, 2024, 8:05 AM EDT - 1 year ago

Lineage Announces Appointment of New Board Member

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Mar 18, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

Mar 13, 2024, 8:00 AM EDT - 1 year ago

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Mar 11, 2024, 8:00 AM EDT - 1 year ago

RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting

Mar 7, 2024, 10:22 PM EST - 1 year ago

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 4:01 PM EST - 1 year ago

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 29, 2024, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024

Feb 13, 2024, 8:00 AM EST - 1 year ago

Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury

Feb 9, 2024, 9:15 AM EST - 1 year ago

Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering

JohnPDaly Aug. 9 at 1:03 PM

$LCTX $MDWD https://x.com/learnbiotech/status/1954120602836496584?s=12

0 · Reply

Trak2 Aug. 9 at 3:53 AM

$LCTX any bold predictions for Tuesday? Winner gets a rocket for his desk. Lol. I’m predicting we’re finally going to hear more about hearing loss.😝trial?

2 · Reply

ChasRiggs Aug. 9 at 1:38 AM

$LCTX kept it right under $1 for options expectation. Intrigued.

1 · Reply

Gromit00 Aug. 8 at 6:01 PM

$LCTX looks like Neal got richer today with Monster, Inc stock up a healthy 6%.

1 · Reply

Wawawiiwa Aug. 8 at 5:05 PM

$LCTX

0 · Reply

broke_millionaire Aug. 8 at 3:53 PM

$LCTX $AVXL $XBI SRPT institutional ownership just skyrocketed to 116%

3 · Reply

Logic102 Aug. 8 at 3:52 PM

2 · Reply

imatisse Aug. 8 at 1:57 PM

0 · Reply

JohnPDaly Aug. 8 at 1:25 PM

$LCTX the race to a trillion bucks has a lot of entrants. https://x.com/geneinvesting/status/1953570907122814991?s=12

2 · Reply

DiligentInvesting Aug. 8 at 12:19 PM

$LCTX I think there´s a rather considerate pump potential with the upcoming ER. Let´s see. STBM.

1 · Reply

alphadog10 Aug. 7 at 9:07 PM

$LCTX Skip to 3 minutes in... https://youtu.be/ILITj3JWd24?si=4eOi80touU1BBjMf

0 · Reply

dannyschell Aug. 7 at 8:58 PM

$LCTX not exactly what I was expecting on the run up to quarterly results. If they were to be spectacular I would expect a bit of a rise not a decline 🤷‍♂️

2 · Reply

imatisse Aug. 7 at 5:44 PM

$LCTX

1 · Reply

Hendo111 Aug. 7 at 4:07 PM

$CEIN $PHAT $LCTX $MBIO

1 · Reply

JohnPDaly Aug. 7 at 4:06 PM

$LCTX FWIW: Morgan Stanley & Co. LLC is serving as financial advisor to Alcon, and Gibson, Dunn & Crutcher LLP is serving as legal advisor to Alcon. Citi is serving as the exclusive financial advisor to STAAR, and Wachtell, Lipton, Rosen & Katz is serving as legal advisor to STAAR.

2 · Reply

Logic102 Aug. 7 at 2:45 PM

$XBI $AVXL $LCTX The Biotech Sector is getting battered--great time to load up on highly undervalued stocks with confirmed science. Anavex is back on the clock with the EMA, so now 95% odds of a positive CHMP decision in Europe in Nov for their safe, low side effect daily Alzheimer's pill. I'm sure they're going to submit a voucher soon for the FDA's new accelerated voucher program.

1 · Reply

Logic102 Aug. 7 at 1:00 PM

$LCTX Handsome Brian, stop posing for photos and get that FDA voucher application submitted. OpRegen is an obvious approval.

1 · Reply

MR_PINKS Aug. 7 at 12:52 PM

$LCTX Where is my boy talking about SANA every other day? The CEO has a history of this..............

3 · Reply

DiligentInvesting Aug. 7 at 12:45 PM

$LCTX Long overdue.

0 · Reply

Invest2live Aug. 7 at 1:41 AM

$NGD 610% already; congrats 🎉🎊🌿🎈checkout $LCTX and $MU

0 · Reply

Invest2live Aug. 6 at 10:14 PM

$LCTX good days are ahead 😊🙏

1 · Reply

Trak2 Aug. 6 at 9:00 PM

$LCTX no big boy pants today.lol

0 · Reply

Market Cap	217.12M
Revenue (ttm)	9.50M
Net Income (ttm)	-18.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-195.89%
Debt to Equity Ratio	0.00

Volume	657,900
Avg Vol	2,668,114
Day's Range	N/A - N/A
Shares Out	228.36M
Stochastic %K	16%
Beta	1.66
Analysts	Strong Sell
Price Target	$3.92